Original Article

You have full text access to this OnlineOpen article

Wnt inhibitors Dkk1 and Sost are downstream targets of BMP signaling through the type IA receptor (BMPRIA) in osteoblasts

  1. Nobuhiro Kamiya1,2,6,*,
  2. Tatsuya Kobayashi3,
  3. Yoshiyuki Mochida4,
  4. Paul B Yu5,
  5. Mitsuo Yamauchi4,
  6. Henry M Kronenberg3,
  7. Yuji Mishina1,2

Article first published online: 14 DEC 2009

DOI: 10.1359/jbmr.090806

Issue

Journal of Bone and Mineral Research

Journal of Bone and Mineral Research

Volume 25, Issue 2, pages 200–210, February 2010

Additional Information

How to Cite

Kamiya, N., Kobayashi, T., Mochida, Y., Yu, P. B., Yamauchi, M., Kronenberg, H. M. and Mishina, Y. (2010), Wnt inhibitors Dkk1 and Sost are downstream targets of BMP signaling through the type IA receptor (BMPRIA) in osteoblasts. Journal of Bone and Mineral Research, 25: 200–210. doi: 10.1359/jbmr.090806

Author Information

  1. 1

    School of Dentistry, University of Michigan, Ann Arbor, MI, USA

  2. 2

    Laboratory of Reproductive and Developmental Toxicology, NIEHS, National Institute of Health, Research Triangle Park, NC, USA

  3. 3

    Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

  4. 4

    Dental Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

  5. 5

    Division of Cardiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

  6. 6

    Center for Excellence in Hip Disorders, Texas Scottish Rite Hospital for Children, Dallas, TX, USA

*Center for Excellence in Hip Disorders, Texas Scottish Rite Hospital for Children, Dallas, TX 75219, USA.

Publication History

  1. Issue published online: 19 FEB 2010
  2. Article first published online: 14 DEC 2009
  3. Manuscript Accepted: 30 JUL 2009
  4. Manuscript Revised: 29 JUN 2009
  5. Manuscript Received: 6 APR 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (511K)

References

  • 1
    Massague J. Receptors for the TGF-β family. Cell. 1992; 69: 1067–1070.
  • 2
    Wrana JL, Attisano L, Wieser R, Ventura F, Massague J. Mechanism of activation of the TGF-β receptor. Nature. 1994; 370: 341–347.
  • 3
    Urist MR. Bone: formation by autoinduction. Science. 1965; 150: 893–899.
  • 4
    Shi Y, Massague J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell. 2003; 113: 685–700.
  • 5
    Keller S, Nickel J, Zhang JL, Sebald W, Mueller TD. Molecular recognition of BMP-2 and BMP receptor IA. Nat Struct Mol Biol. 2004; 11: 481–488.
  • 6
    Hatta T, Konishi H, Katoh E, et al. Identification of the ligand-binding site of the BMP type IA receptor for BMP-4. Biopolymers. 2000; 55: 399–406.
  • 7
    Wozney JM. The bone morphogenetic protein family and osteogenesis. Mol Reprod Dev. 1992; 32: 160–167.
  • 8
    Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. Growth Factors. 2004; 22: 233–241.
  • 9
    Shore EM, Xu M, Feldman GJ, et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet. 2006; 38: 525–527.
  • 10
    Yu PB, Deng DY, Lai CS, et al. BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat Med. 2008; 14: 1363–1369.
  • 11
    Zhang H, Bradley A. Mice deficient for BMP2 are nonviable and have defects in amnion/chorion and cardiac development. Development. 1996; 122: 2977–2986.
  • 12
    Winnier G, Blessing M, Labosky PA, Hogan BL. Bone morphogenetic protein-4 is required for mesoderm formation and patterning in the mouse. Genes Dev. 1995; 9: 2105–2116.
  • 13
    Mishina Y, Suzuki A, Ueno N, Behringer RR. Bmpr encodes a type I bone morphogenetic protein receptor that is essential for gastrulation during mouse embryogenesis. Genes Dev. 1995; 9: 3027–3037.
  • 14
    Kamiya N, Ye L, Kobayashi T, et al. BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway. Development. 2008; 135: 3801–3811.
  • 15
    Kamiya N, Ye L, Kobayashi T, et al. Disruption of BMP signaling in osteoblasts through type IA receptor (BMPRIA) increases bone mass. J Bone Miner Res. 2008; 23: 2007–2017.
  • 16
    Harada S, Rodan GA. Control of osteoblast function and regulation of bone mass. Nature. 2003; 423: 349–355.
  • 17
    Baron R, Rawadi G, Roman-Roman S. Wnt signaling: a key regulator of bone mass. Curr Top Dev Biol. 2006; 76: 103–127.
  • 18
    Krishnan V, Bryant HU, Macdougald OA. Regulation of bone mass by Wnt signaling. J Clin Invest. 2006; 116: 1202–1209.
  • 19
    Hartmann C. A Wnt canon orchestrating osteoblastogenesis. Trends Cell Biol. 2006; 16: 151–158.
  • 20
    Glass DA 2nd, Karsenty G. Molecular bases of the regulation of bone remodeling by the canonical Wnt signaling pathway. Curr Top Dev Biol. 2006; 73: 43–84.
  • 21
    Rawadi G, Vayssiere B, Dunn F, Baron R, Roman-Roman S. BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. J Bone Miner Res. 2003; 18: 1842–1853.
  • 22
    Bain G, Muller T, Wang X, Papkoff J. Activated β-catenin induces osteoblast differentiation of C3H10T1/2 cells and participates in BMP2-mediated signal transduction. Biochem Biophys Res Commun. 2003; 301: 84–91.
  • 23
    Mbalaviele G, Sheikh S, Stains JP, et al. β-Catenin and BMP-2 synergize to promote osteoblast differentiation and new bone formation. J Cell Biochem. 2005; 94: 403–418.
  • 24
    Winkler DG, Sutherland MS, Ojala E, et al. Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins. J Biol Chem. 2005; 280: 2498–2502.
  • 25
    Nakashima A, Katagiri T, Tamura M. Cross-talk between Wnt and bone morphogenetic protein 2 (BMP-2) signaling in differentiation pathway of C2C12 myoblasts. J Biol Chem. 2005; 280: 37660–37668.
  • 26
    Simpson AH, Mills L, Noble B. The role of growth factors and related agents in accelerating fracture healing. J Bone Joint Surg Br. 2006; 88: 701–705.
  • 27
    Mishina Y, Hanks MC, Miura S, Tallquist MD, Behringer RR. Generation of Bmpr/Alk3 conditional knockout mice. Genesis. 2002; 32: 69–72.
  • 28
    Soriano P. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet. 1999; 21: 70–71.
  • 29
    DasGupta R, Fuchs E. Multiple roles for activated LEF/TCF transcription complexes during hair follicle development and differentiation. Development. 1999; 126: 4557–4568.
  • 30
    Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(–ΔΔC(t)) method. Methods. 2001; 25: 402–408.
  • 31
    Fujita N, Kajita M, Taysavang P, Wade PA. Hormonal regulation of metastasis-associated protein 3 transcription in breast cancer cells. Mol Endocrinol. 2004; 18: 2937–2949.
  • 32
    Yu PB, Hong CC, Sachidanandan C, et al. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol. 2008; 4: 33–41.
  • 33
    Ai M, Holmen SL, Van Hul W, Williams BO, Warman ML. Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling. Mol Cell Biol. 2005; 25: 4946–4955.
  • 34
    Li X, Liu P, Liu W, et al. Dkk2 has a role in terminal osteoblast differentiation and mineralized matrix formation. Nat Genet. 2005; 37: 945–952.
  • 35
    Patel MS, Karsenty G. Regulation of bone formation and vision by LRP5. N Engl J Med. 2002; 346: 1572–1574.
  • 36
    Li X, Zhang Y, Kang H, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005; 280: 19883–19887.
  • 37
    Semenov M, Tamai K, He X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem. 2005; 280: 26770–26775.
  • 38
    Bodine PV, Zhao W, Kharode YP, et al. The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice. Mol Endocrinol. 2004; 18: 1222–1237.
  • 39
    Miyazono K. Signal transduction by bone morphogenetic protein receptors: functional roles of Smad proteins. Bone. 1999; 25: 91–93.
  • 40
    Fujii M, Takeda K, Imamura T, et al. Roles of bone morphogenetic protein type I receptors and Smad proteins in osteoblast and chondroblast differentiation. Mol Biol Cell. 1999; 10: 3801–3813.
  • 41
    Xu X, Han J, Ito Y, Bringas P Jr, Deng C, Chai Y. Ectodermal Smad4 and p38 MAPK are functionally redundant in mediating TGF-β/BMP signaling during tooth and palate development. Dev Cell. 2008; 15: 322–329.
  • 42
    Zuzarte-Luis V, Montero JA, Rodriguez-Leon J, Merino R, Rodriguez-Rey JC, Hurle JM. A new role for BMP5 during limb development acting through the synergic activation of Smad and MAPK pathways. Dev Biol. 2004; 272: 39–52.
  • 43
    Tseng YH, Kokkotou E, Schulz TJ, et al. New role of bone morphogenetic protein 7 in brown adipogenesis and energy expenditure. Nature. 2008; 454: 1000–1004.
  • 44
    Inagaki K, Otsuka F, Miyoshi T, et al. p38-Mitogen-activated protein kinase stimulated steroidogenesis in granulosa cell-oocyte cocultures: role of bone morphogenetic proteins 2 and 4. Endocrinology. 2009; 150: 1921–1930.
  • 45
    Nohe A, Keating E, Knaus P, Petersen NO. Signal transduction of bone morphogenetic protein receptors. Cell Signal. 2004; 16: 291–299.
  • 46
    Huelsken J, Vogel R, Erdmann B, Cotsarelis G, Birchmeier W. β-Catenin controls hair follicle morphogenesis and stem cell differentiation in the skin. Cell. 2001; 105: 533–545.
  • 47
    Barrow JR, Thomas KR, Boussadia-Zahui O, et al. Ectodermal Wnt3/β-catenin signaling is required for the establishment and maintenance of the apical ectodermal ridge. Genes Dev. 2003; 17: 394–409.
  • 48
    Guo X, Day TF, Jiang X, Garrett-Beal L, Topol L, Yang Y. Wnt/β-catenin signaling is sufficient and necessary for synovial joint formation. Genes Dev. 2004; 18: 2404–2417.
  • 49
    He XC, Zhang J, Tong WG, et al. BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-β-catenin signaling. Nat Genet. 2004; 36: 1117–1121.
  • 50
    Dean CH, Miller LA, Smith AN, Dufort D, Lang RA, Niswander LA. Canonical Wnt signaling negatively regulates branching morphogenesis of the lung and lacrimal gland. Dev Biol. 2005; 286: 270–286.
  • 51
    Zhang J, He XC, Tong WG, et al. Bone morphogenetic protein signaling inhibits hair follicle anagen induction by restricting epithelial stem/progenitor cell activation and expansion. Stem Cells. 2006; 24: 2826–2839.
  • 52
    Chen Y, Whetstone HC, Youn A, et al. Beta-catenin signaling pathway is crucial for bone morphogenetic protein 2 to induce new bone formation. J Biol Chem. 2007; 282: 526–533.
  • 53
    Mukhopadhyay M, Shtrom S, Rodriguez-Esteban C, et al. Dickkopf1 is required for embryonic head induction and limb morphogenesis in the mouse. Dev Cell. 2001; 1: 423–434.
  • 54
    Grotewold L, Ruther U. The Wnt antagonist Dickkopf-1 is regulated by BMP signaling and c-Jun and modulates programmed cell death. EMBO J. 2002; 21: 966–975.
  • 55
    Sutherland MK, Geoghegan JC, Yu C, et al. Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation. Bone. 2004; 35: 828–835.
  • 56
    Ohyama Y, Nifuji A, Maeda Y, Amagasa T, Noda M. Spaciotemporal association and bone morphogenetic protein regulation of sclerostin and osterix expression during embryonic osteogenesis. Endocrinology. 2004; 145: 4685–4692.
  • 57
    Semenov MV, Tamai K, Brott BK, Kuhl M, Sokol S, He X. Head inducer Dickkopf-1 is a ligand for Wnt coreceptor LRP6. Curr Biol. 2001; 11: 951–961.
  • 58
    Morvan F, Boulukos K, Clement-Lacroix P, et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res. 2006; 21: 934–945.
  • 59
    Li J, Sarosi I, Cattley RC, et al. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone. 2006; 39: 754–766.
  • 60
    Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003; 349: 2483–2494.
  • 61
    Li X, Ominsky MS, Niu QT, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008; 23: 860–869.
  • 62
    Balemans W, Ebeling M, Patel N, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001; 10: 537–543.
  • 63
    Brunkow ME, Gardner JC, Van Ness J, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001; 68: 577–589.
  • 64
    Balemans W, Patel N, Ebeling M, et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet. 2002; 39: 91–97.
  • 65
    Staehling-Hampton K, Proll S, Paeper BW, et al. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet. 2002; 110: 144–152.
  • 66
    Suzuki A, Guicheux J, Palmer G, et al. Evidence for a role of p38 MAP kinase in expression of alkaline phosphatase during osteoblastic cell differentiation. Bone. 2002; 30: 91–98.
  • 67
    Yuge L, Okubo A, Miyashita T, et al. Physical stress by magnetic force accelerates differentiation of human osteoblasts. Biochem Biophys Res Commun. 2003; 311: 32–38.
  • 68
    Yuge L, Hide I, Kumagai T, et al. Cell differentiation and p38(MAPK) cascade are inhibited in human osteoblasts cultured in a three-dimensional clinostat. In Vitro Cell Dev Biol Anim. 2003; 39: 89–97.
  • 69
    Lee DY, Yeh CR, Chang SF, et al. Integrin-mediated expression of bone formation-related genes in osteoblast-like cells in response to fluid shear stress: roles of extracellular matrix, Shc, and mitogen-activated protein kinase. J Bone Miner Res. 2008; 23: 1140–1149.
  • 70
    Wingerter S, Tucci M, Bumgardner J, Benghuzzi H. Evaluation of short-term healing following sustained delivery of osteoinductive agents in a rat femur drill defect model. Biomed Sci Instrum. 2007; 43: 188–193.
  • 71
    Gautschi OP, Frey SP, Zellweger R. Bone morphogenetic proteins in clinical applications. Aust NZ J Surg. 2007; 77: 626–631.
  • 72
    Yoon BS, Ovchinnikov DA, Yoshii I, Mishina Y, Behringer RR, Lyons KM. Bmpr1a and Bmpr1b have overlapping functions and are essential for chondrogenesis in vivo. Proc Natl Acad Sci USA. 2005; 102: 5062–5067.
  • 73
    Bandyopadhyay A, Tsuji K, Cox K, Harfe BD, Rosen V, Tabin CJ. Genetic analysis of the roles of BMP2, BMP4, and BMP7 in limb patterning and skeletogenesis. PLoS Genet. 2006; 2: e216.
  • 74
    Tsuji K, Bandyopadhyay A, Harfe BD, et al. BMP2 activity, although dispensable for bone formation, is required for the initiation of fracture healing. Nat Genet. 2006; 38: 1424–1429.
  • 75
    Rountree RB, Schoor M, Chen H, et al. BMP receptor signaling is required for postnatal maintenance of articular cartilage. PLoS Biol. 2004; 2: e355.
View Full Article (HTML) Get PDF (511K)